微創醫療(00853.HK)附屬微創神通醫療獲戰投1.5億元
格隆匯7月24日丨微創醫療(00853.HK)發佈公告,於2020年7月24日,集團若干成員公司訂立協議,據此:(i)望道通生物技術及投資者上海良弘企業管理諮詢中心(有限合夥)同意向目標公司微創神通醫療科技(上海)有限公司注入新資本;(ii)附屬公司同意提供貸款予望道通生物技術;及(iii)集團同意於第一份協議完成後向目標公司集團供應原材料,包括醫療器械及設備。
目標公司為一間於中國成立的有限公司,主要從事神經介入醫療器械的研究與開發、生產和銷售。目標公司於第一份協議日期由公司附屬公司擁有83%。
根據協議,望道通生物技術及投資者將向目標公司注資合計人民幣1.5億元,其中望道通生物技術及投資者將分別注資人民幣1.15億元及人民幣3500萬元。緊隨第一份協議完成後,公司於目標公司的實際股權將由當前的83%攤薄至約69.89%,而目標公司將仍為公司的附屬公司。
此外,附屬公司將向望道通生物技術提供本金額人民幣1.15億元的18個月有抵押定期貸款,貸款將按年利率5%計息。
根據第三份協議,集團成員公司將向目標公司集團的成員公司供應原材料(包括但不限於醫療器械及設備)及提供採購服務。
公司稱,目標公司的產品涉及尖端技術,研發、臨牀試驗、監管註冊及商業化涉及巨大成本。因此,目標公司對其發展計劃的實施及執行有大量資金需求。增資將為目標公司的發展提供額外資金。
此外,集團採取一項鼓勵僱員積極參與業務投資的戰略,以使僱員可以在業務中擁有個人權益並分享成果。為了積極促進附屬公司及聯營公司的業務發展和孵化,並鼓勵集團高級管理層積極參與此項投資、激發高級管理層的創業精神,並促進集團的戰略目標,公司考慮向高級管理層提供財務資助,以投資公司的附屬公司及聯營公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.